Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EVGN Stock Forecast 2026-2027
$0.80
Current Price
$7.87M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EVGN Price Targets
+182.9%
To High Target of $2.25
+182.9%
To Median Target of $2.25
+182.9%
To Low Target of $2.25
EVGN Price Momentum
-1.2%
1 Week Change
-8.0%
1 Month Change
-17.5%
1 Year Change
-27.3%
Year-to-Date Change
-67.1%
From 52W High of $2.42
+10.4%
From 52W Low of $0.72
📊 TOP ANALYST CALLS
Did EVGN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Evogene is one of their latest high-conviction picks.
Latest EVGN Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, EVGN has a bullish consensus with a median price target of $2.25 (ranging from $2.25 to $2.25). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.80, the median forecast implies a 182.9% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EVGN Analyst Ratings
1
Buy
0
Hold
0
Sell
EVGN Price Target Range
Low
$2.25
Average
$2.25
High
$2.25
Current: $0.80
Latest EVGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EVGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2025 | Lake Street | Ben Klieve | Buy | Maintains | $3.50 |
| Aug 23, 2024 | Lake Street | Ben Klieve | Buy | Maintains | $12.00 |
| Oct 2, 2023 | Alliance Global Partners | Ben Haynor | Buy | Initiates | $1.85 |
| Aug 18, 2023 | Lake Street | Ben Klieve | Buy | Maintains | $3.00 |
| Jul 21, 2023 | Roth MKM | Buy | Maintains | $N/A | |
| May 2, 2023 | Lake Street | Ben Klieve | Buy | Initiates | $2.00 |
| Sep 12, 2022 | Aegis Capital | Nathan Weinstein | Buy | Maintains | $8.00 |
| Sep 2, 2022 | Roth MKM | Buy | Maintains | $N/A | |
| Oct 8, 2021 | Roth Capital | Brian Wright | Buy | Initiates | $7.00 |
| Jul 29, 2021 | Aegis Capital | Buy | Initiates | $N/A | |
| Dec 1, 2020 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Nov 12, 2014 | Credit Suisse | Outperform | Maintains | $22.00 | |
| Dec 17, 2013 | Deutsche Bank | Buy | Initiates | $N/A | |
| Dec 16, 2013 | Credit Suisse | Outperform | Initiates | $N/A |
Evogene Ltd. (EVGN) Competitors
The following stocks are similar to Evogene based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Evogene Ltd. (EVGN) Financial Data
Evogene Ltd. has a market capitalization of $7.87M with a P/E ratio of 0.3x. The company generates $3.85M in trailing twelve-month revenue with a -220.2% profit margin.
Revenue growth is -80.5% quarter-over-quarter, while maintaining an operating margin of -1,581.5% and return on equity of -100.7%.
Valuation Metrics
Market Cap
$7.87M
Enterprise Value
$9.41M
P/E Ratio
0.3x
PEG Ratio
0.0x
Price/Sales
2.2x
Growth & Margins
Revenue Growth (YoY)
-80.5%
Gross Margin
-627.4%
Operating Margin
-1,581.5%
Net Margin
-220.2%
EPS Growth
-80.5%
Financial Health
Cash/Price Ratio
+164.7%
Current Ratio
4.5x
Debt/Equity
18.4x
ROE
-100.7%
ROA
-28.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Evogene Ltd. (EVGN) Business Model
About Evogene Ltd.
What They Do
Develops innovative biotechnology solutions.
Business Model
The company utilizes a computational predictive biology platform to create products for agriculture, pharmaceuticals, and industrial applications. It generates revenue through collaborations with leading industry players to commercialize its discoveries, focusing on optimizing crop traits and addressing health challenges.
Additional Information
Headquartered in Rehovot, Israel, Evogene is positioned as a key player in biotechnology, contributing to advancements in productivity and sustainability. Its focus on leveraging big data analytics and extensive databases enhances its ability to meet global demands for biologically driven solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
117
CEO
Mr. Ofer Haviv CPA
Country
Israel
IPO Year
2010
Website
www.evogene.comEvogene Ltd. (EVGN) Latest News & Analysis
Latest News
Quick Summary
Evogene Ltd. (NASDAQ: EVGN) reported non-compliance with Nasdaq Rule 5550(a)(2) due to its share price closing below $1.00 for 30 consecutive business days.
Why It Matters
Evogene's non-compliance with Nasdaq's price rule may lead to delisting, affecting investor confidence and stock liquidity. A low share price can signal underlying business challenges.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Casterra Ag Ltd., a subsidiary of Evogene Ltd., focuses on high-yield castor seed varieties and integrated farming solutions for sustainable bio-based products.
Why It Matters
Casterra's advancements in high-yield castor seed varieties position it favorably in the sustainable bio-products market, potentially driving growth and attracting investor interest in green industries.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Evogene Ltd. (NASDAQ: EVGN) will present at the BIO-Europe Spring 2026 conference in Lisbon, Portugal, from March 23-25, 2026, focusing on its generative AI design in pharmaceuticals and agriculture.
Why It Matters
Evogene's participation in BIO-Europe Spring 2026 highlights its advancements in AI-driven drug design, potentially attracting partnerships and investment in biotech innovation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Evogene Ltd. (EVGN) held its Q4 2025 earnings call, discussing financial performance and strategic developments. Further details on revenue and projections were shared during the call.
Why It Matters
The Q4 2025 earnings call provides insights into Evogene Ltd.'s financial performance, growth prospects, and strategic direction, which can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Evogene Ltd. (NASDAQ: EVGN) announced its Q4 and full-year 2025 financial results today, March 5, 2026. A conference call is scheduled for 9:00 AM ET.
Why It Matters
Evogene Ltd.'s financial results reveal company performance, impacting stock valuation and investor sentiment, particularly in the AI-driven pharmaceutical and agricultural sectors.
Source: PRNewsWire
Market Sentiment:
Neutral
Evogene Releases CEO Letter to Shareholders
1 month ago
Quick Summary
Evogene Ltd. (Nasdaq: EVGN) announced an update on its strategic progress and outlook in a shareholder letter from CEO Ofer Haviv, focusing on its generative AI capabilities in pharmaceuticals and agriculture.
Why It Matters
Evogene's update on strategic progress signals advancements in AI-driven drug and agricultural solutions, potentially enhancing market position and attracting investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About EVGN Stock
What is Evogene Ltd.'s (EVGN) stock forecast for 2026?
Based on our analysis of 5 Wall Street analysts, Evogene Ltd. (EVGN) has a median price target of $2.25. The highest price target is $2.25 and the lowest is $2.25.
Is EVGN stock a good investment in 2026?
According to current analyst ratings, EVGN has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.80. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EVGN stock?
Wall Street analysts predict EVGN stock could reach $2.25 in the next 12 months. This represents a 182.9% increase from the current price of $0.80. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Evogene Ltd.'s business model?
The company utilizes a computational predictive biology platform to create products for agriculture, pharmaceuticals, and industrial applications. It generates revenue through collaborations with leading industry players to commercialize its discoveries, focusing on optimizing crop traits and addressing health challenges.
What is the highest forecasted price for EVGN Evogene Ltd.?
The highest price target for EVGN is $2.25 from at , which represents a 182.9% increase from the current price of $0.80.
What is the lowest forecasted price for EVGN Evogene Ltd.?
The lowest price target for EVGN is $2.25 from at , which represents a 182.9% increase from the current price of $0.80.
What is the overall EVGN consensus from analysts for Evogene Ltd.?
The overall analyst consensus for EVGN is bullish. Out of 5 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $2.25.
How accurate are EVGN stock price projections?
Stock price projections, including those for Evogene Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 4:47 AM UTC